evipedia.ai
← Back

Dandelion Root to Treat Cancer

Evidence Review created on 10/23/2026 using AI4L / Opus 5.5

Also known as: Taraxacum officinale Root, Taraxaci officinalis radix, Dandelion Root Extract, DRE, Dandelion Root Tea

Motivation

Dandelion root (Taraxacum officinale) is the long taproot of the familiar yellow-flowered weed, sold as roasted tea, capsules and liquid extracts. It draws attention as a possible cancer treatment because laboratory groups have tested whether a simple hot-water extract of the root can push cancer cells to self-destruct while leaving healthy cells alone, an unusual claim for an inexpensive plant found in most gardens.

The root has a long history in Chinese, Arabic, European and Native American herbal traditions as a bitter digestive remedy and a way to increase urine flow. Interest in cancer grew after a Canadian oncology group described patients with blood cancers who were drinking the tea, a small first human trial was planned, and online posts about the root spread widely.

For health-focused adults facing a cancer diagnosis and willing to add demanding measures to their care, this review examines the laboratory, animal and human evidence on dandelion root as a cancer treatment, its risks, including drug interactions and the consequences of delaying proven therapy, and what is known about dosing, product quality and monitoring.

Benefits - Risks - Protocol - Conclusion

This section lists overview articles and key primary papers on dandelion root as a cancer treatment.

No directly relevant content on dandelion root and cancer was found from Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension or Lifespan.io: their sites mention dandelion only as a food, coffee substitute or fiber source, or not at all.

Grokipedia

Taraxacum officinale

An AI-written encyclopedia entry on the common dandelion covering botany, traditional uses and pharmacology; it notes that the anticancer findings come only from cell and animal models.

Examine

Dandelion

Examine’s dandelion page lists one human trial of 17 participants with a diuretic (urine-increasing) outcome and states that supplementation cannot be recommended given scant human evidence; it reports no cancer outcomes.

ConsumerLab

Dandelion Tea & Supplements: Health Benefits and Safety

ConsumerLab’s dandelion article (full text members-only) reviews evidence for cancer and other uses, side effects and drug interactions, with an April 2026 update on lead in dandelion tea.

Systematic Reviews

This section lists the systematic reviews that cover dandelion, none of which pools human cancer outcomes, plus one on the principal risk of delayed treatment.

No systematic review or meta-analysis covers any human anticancer effect of dandelion root, so the claimed benefit is unrepresented at this level; the principal risk, delaying conventional cancer treatment, is represented only by a review of treatment delay in general, not of dandelion use.

Mechanism of Action

Dandelion root is a mixture, not a single drug. Its hot-water extract contains triterpenes (sterol-like plant compounds: taraxasterol, lupeol, α- and β-amyrin), sesquiterpene lactones (bitter compounds), phenolic acids (plant antioxidant acids: chicoric and chlorogenic acid) and inulin (a fermentable fiber).

  • Death-receptor signalling: In leukemia cells, the Windsor group, whose lead scientists are patent inventors on the extract, found early activation of caspase-8 (the enzyme that starts receptor-triggered apoptosis, or programmed cell death); cells lacking working FADD (an adaptor linking death receptors to caspase-8) resisted the extract (Ovadje 2011).
  • Mitochondrial stress: The extract raised reactive oxygen species (ROS, chemically reactive oxygen molecules) in mitochondria from colon cancer cells but not normal cells, and colon cancer cells still died when caspase-8 was blocked (Ovadje 2016).
  • Growth-signal suppression: Other groups report lower PI3K/Akt (a growth-and-survival signalling pathway) activity (Duan 2021) and activation of AMPK (a cellular energy sensor) (Rehman 2017).
  • Competing reading: The concentrations that halved colon cancer cell viability were 2.0–3.5 mg/mL, levels not shown to be reachable in human blood; isolated triterpenes were weaker than the whole extract (Ovadje 2016); another root extract did not slow breast or prostate cancer cell growth (Sigstedt 2008).
  • Pharmacology: Human half-life, selectivity, tissue distribution and metabolism are unknown; only a rat study of taraxasterol levels exists (Zhang 2015). In rats, dandelion tea lowered CYP1A2 and CYP2E1 (liver enzymes that break down drugs) and raised UGT (an enzyme that tags drugs for excretion) activity (Maliakal 2001).

Historical Context & Evolution

Dandelion root was first used as food and medicine, not as a cancer treatment. Arabic, European and Native American herbalists gave it as a bitter tonic for digestion and the liver and to increase urine flow; Chinese medicine used the whole plant for breast abscesses and swellings (Memorial Sloan Kettering), and some Chinese and Native American traditions applied it to leukemia and breast cancer (Ovadje 2011); roasted root became a coffee substitute. The European Medicines Agency still lists traditional uses limited to mild digestive complaints, loss of appetite and urinary flushing (EMA).

Cancer interest grew from scattered laboratory findings. A Japanese team reported in 1999 that a root extract of a related species suppressed chemically induced skin tumors in mice (Takasaki 1999). Beginning with a 2009 patient, Windsor oncologist Caroline Hamm described patients with treatment-resistant myelomonocytic leukemia whose counts improved on dandelion root tea, and with biochemist Siyaram Pandey produced cell and mouse studies across several cancers (Hamm 2013; Ovadje 2016). The group patented a dandelion root medicament (US10179156B2) and planned a small human trial (Canadian Broadcasting Corporation).

What changed since then is volume, not class, of evidence: laboratories in China, Pakistan and the Middle East added cell and rodent studies (Zhu 2017; Rehman 2017; Nassan 2018), while the planned trial reported no results. Viral posts claiming the root kills “98% of cancer cells” overstated a cell-dish finding (PolitiFact). Neither supporters nor critics have human trial data, so the question remains open rather than settled.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: there are no controlled human trials of dandelion root in cancer, only uncontrolled case reports and laboratory studies.

Medium 🟩 🟩

No benefit reaches Medium: no single controlled trial or comparative observational study of dandelion root in people with cancer exists; the human data are uncontrolled case reports.

Low 🟩

Blood-Count Remission in Myelomonocytic Leukemia

Windsor oncologists reported patients with treatment-resistant myelomonocytic leukemia (blood cancers of monocyte-type white cells) whose counts normalized on dandelion root tea (Hamm 2013); one relapsed after 3 months. A capsule user also took many supplements (Rahmat & Damon 2018). Evidence is uncontrolled and confounded.

Magnitude: One patient remained in complete blood-count response 5 months after diagnosis on three cups daily (white cells 4.2 × 10⁹/L, monocytes 0.8 × 10⁹/L; no control group); in the capsule case, marrow blasts (immature leukemia cells) had been below 5% since March 2013, before dandelion began in early 2015 (no control group); the case report’s abstract credits both extracts for the marrow improvement, but its full-text timeline places the improvement before dandelion use.

Increased Urine Output ⭕️ Not Central to Treat Cancer

A dandelion preparation increased urination in 17 volunteers, an effect the European Union monograph registers as a traditional use for flushing the urinary tract (Clare 2009; EMA). Indirect: the trial used fresh-leaf extract, not root, and had no control group. This bears on urinary complaints, not cancer.

Magnitude: Mean daily urination frequency rose from 8.0 on the control day to 9.0 on the dosing day, compared with each participant’s own baseline (no control group); the rise was concentrated in the 5 hours after the first dose, the urine-to-fluid-intake ratio rose after the second dose, and the third dose changed neither.

Speculative 🟨

Anticancer Activity in Cells and Rodents ⚠️ Conflicted

Cell and animal basis only. Root extract killed colon and esophageal cancer cells and slowed mouse tumors (Ovadje 2016; Duan 2021); another left breast and prostate cells unaffected (Sigstedt 2008). Net: effect varies by extract.

Added Effect With Chemotherapy

Cell-culture basis only. Adding root extract to paclitaxel or mitoxantrone (chemotherapy drugs) increased prostate cancer cell death versus either drug alone (Nguyen 2019); the combination is untested in patients.

Reduced Cancer-Cell Invasion and Migration

Cell-culture basis only. Root extract blocked breast cancer cell invasion into collagen (Sigstedt 2008) and slowed colon cancer cell migration (Ovadje 2016); no metastasis data exist.

Skin-Tumor Prevention in Mice ⭕️ Not Central to Treat Cancer

Animal basis only. Root extract of the related Taraxacum japonicum suppressed chemically induced skin tumors in mice (Takasaki 1999). This bears on cancer prevention, not treatment.

Appetite and Digestive Relief ⭕️ Not Central to Treat Cancer

Traditional-use basis only. The European Union monograph registers dandelion root for mild digestive complaints and loss of appetite on long-standing use (EMA); no controlled human trial has tested either. This bears on digestion, not cancer.

Benefit-Modifying Factors

  • Genetic polymorphisms: No study has examined inherited gene variants. Tumor genetics may matter: the extract killed colon cancer cells regardless of p53 (a tumor-suppressor gene) status (Ovadje 2016), while leukemia cells lacking FADD function resisted it (Ovadje 2011).
  • Baseline biomarker levels: No human data link baseline labs to response. In the Windsor case reports, monocyte counts rose when tea intake fell below three cups daily (Hamm 2013).
  • Sex-based differences: No sex-specific benefit data exist. Estrogen-like activity of an ethanol dandelion extract in breast cancer cells (Oh 2015) leaves benefit in hormone-sensitive breast or uterine cancers uncertain.
  • Pre-existing health conditions: Reported human responses are confined to myelomonocytic leukemias; solid tumors have only cell and animal data. Prior chemotherapy preceded tea use in most reported cases, blurring attribution (Hamm 2013).
  • Age-related considerations: Reported patients were 60–76 years old (Rahmat & Damon 2018); no age-stratified data exist, so benefit at the older end of the target range is unknown.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no controlled human trial of dandelion root has recorded adverse events; the human harm data are case reports and patch-test series.

Medium 🟥 🟥

No risk reaches Medium: the only comparative human data on forgoing cancer treatment concern alternative medicine in general, not dandelion root, which makes them indirect.

Low 🟥

Delayed or Forgone Effective Cancer Treatment

US registry studies by Johnson’s Yale group found higher mortality when alternative medicine replaced treatment and more refusal of surgery, chemotherapy and radiotherapy among complementary-medicine users (Johnson 2018a; Johnson 2018b). Indirect: dandelion root itself was not studied.

Magnitude: Alternative medicine alone versus conventional treatment: five-year survival 54.7% versus 78.3%; hazard ratio (HR, relative rate of death over time) 2.50 (95% CI, the range likely to hold the true value, 1.88–3.27). Complementary-medicine users had 82.2% versus 86.6% five-year survival (HR 2.08, 95% CI 1.50–2.90), falling to HR 1.39 (95% CI 0.83–2.33) once treatment refusal was modeled.

Allergic and Contact Skin Reactions

Dandelion contains sesquiterpene lactones, the allergens behind Compositae (daisy-family) dermatitis. All seven patients with suspected dandelion dermatitis reacted on patch testing (Lovell 1991); in a larger series, reactions occurred only in people with eczema (Jovanović 2004).

Magnitude: 3 of 235 tested adults (1.3%) reacted to dandelion extract, all with eczema, versus none of the 49 healthy volunteers.

Altered Levels of Narrow-Margin Drugs

A transplant recipient reached toxic cyclosporine and sirolimus levels after a multi-herb tea containing dandelion (Kwan 2014; Memorial Sloan Kettering Cancer Center (MSKCC)). Lab and rat data add CYP3A4 (the main drug-clearing liver enzyme) inhibition (Dufay 2014) and a possible imatinib, dasatinib and nilotinib interaction (Alzoman 2019).

Magnitude: Not quantified in available studies. No controlled human pharmacokinetic (drug absorption and clearance) study has measured dandelion’s effect on drug levels; only a single multi-herb case report exists.

Digestive Upset

MSKCC’s herb monograph lists heartburn, stomach inflammation and dyspepsia (indigestion) among oral reactions, and mild diarrhea with overdosage (MSKCC); an Italian survey of herbal users recorded gastrointestinal reactions after dandelion (Cuzzolin 2006). Evidence is monograph listings and self-report without trial rates.

Magnitude: Not quantified in available studies. No controlled human trial of dandelion root has recorded digestive adverse-event rates, and neither source gives a dandelion-specific frequency.

Low Blood Sugar

An emergency department reported hypoglycemia (abnormally low blood glucose) after dandelion ingestion (Goksu 2010); the MSKCC herb monograph lists low blood sugar among side effects (MSKCC). Evidence is a single case report.

Magnitude: Not quantified in available studies. Only one case report exists, without a comparison group.

Liver and Bile-Flow Injury

A 36-year-old developed cholestatic liver injury (impaired bile flow) after a detox tea of dandelion root and five other herbs (Niazi 2022). Regulators advise against use in biliary disease because of possible bile stimulation (EMA).

Magnitude: Not quantified in available studies. The human evidence is a single multi-ingredient case report.

Oxalate Injury With Very High Intake

A man with chronic kidney disease who drank 10–15 cups of dandelion tea daily for 6 months developed digital necrosis (tissue death in fingers) linked to excess oxalate (a compound that forms crystals in tissues) (Moriarty 2013; MSKCC). Risk applies to very high intake with poor kidney function.

Magnitude: Not quantified in available studies. Only one case report exists, without a comparison group.

Speculative 🟨

Estrogen-Like Stimulation of Hormone-Sensitive Tumors

Cell and animal basis only. An ethanol extract of Taraxacum mongolicum increased breast cancer cell proliferation through the estrogen receptor and slightly raised uterine weight in immature rats (Oh 2015).

Lower Peak Antibiotic Levels

Animal basis only. A Taraxacum mongolicum extract cut peak ciprofloxacin (a quinolone antibiotic) blood levels by 73% in rats, with overall exposure unchanged (Zhu 1999), a concern during infection-prone cancer treatment.

Contaminated Products

No human harm documented. ConsumerLab posted an update on lead in dandelion tea (ConsumerLab); urban wild dandelions carried pathogenic bacteria (Boguś 2023).

Risk-Modifying Factors

  • Genetic polymorphisms: No pharmacogenetic data exist. People with reduced CYP3A4 or CYP1A2 activity who take narrow-margin drugs would theoretically be most exposed to added enzyme inhibition (theoretical).
  • Baseline biomarker levels: Abnormal liver enzymes or bilirubin flag biliary or liver disease, where use is not recommended (EMA); reduced kidney function raises concern given the oxalate case (Moriarty 2013).
  • Sex-based differences: No sex-specific harm data exist. Women with hormone-receptor-positive breast or uterine cancers face the unresolved estrogen question (Oh 2015); use in pregnancy and breastfeeding is not recommended (EMA).
  • Pre-existing health conditions: Atopic eczema (allergy-linked eczema) or daisy-family allergy (Jovanović 2004), gallstones or bile-duct disease, chronic kidney disease, insulin-treated diabetes and organ transplantation on immunosuppressants each raise risk.
  • Age-related considerations: Older adults more often take diuretics, diabetes drugs and other interacting medicines and have lower kidney reserve; the EU monograph does not recommend use under 12 years (EMA).

Key Interactions & Contraindications

  • Calcineurin and mTOR inhibitors (immunosuppressants blocking an immune enzyme or a growth regulator; cyclosporine, tacrolimus, sirolimus): Caution — toxic levels in one multi-herb tea case (Kwan 2014) and lab CYP3A4 inhibition (Dufay 2014); consequence kidney or nerve toxicity. Mitigation: trough (pre-dose) level checks.
  • Tyrosine kinase inhibitors (imatinib, dasatinib, nilotinib): Caution (theoretical) — rat data flag a pharmacokinetic interaction (Alzoman 2019); consequence loss of leukemia control or added toxicity. Mitigation: disclosure to the hematologist and response monitoring.
  • CYP1A2 substrates (theophylline, clozapine, tizanidine): Monitor (theoretical) — rat CYP1A2 activity fell to 15% of control (Maliakal 2001); consequence raised drug levels and toxicity. Mitigation: watching for drug side effects.
  • UGT-cleared drugs (irinotecan, mycophenolate, lamotrigine): Monitor (theoretical) — rat UGT activity rose to 244% of control (Maliakal 2001); consequence altered drug exposure. Mitigation: prescriber review before combining.
  • Quinolone antibiotics (ciprofloxacin, levofloxacin): Caution (theoretical) — peak ciprofloxacin fell 73% in rats, overall exposure unchanged (Zhu 1999); consequence possibly weaker infection control. Mitigation: doses separated by at least 2 hours.
  • Diuretics and lithium (furosemide, hydrochlorothiazide, lithium): Monitor (theoretical) — dandelion’s diuretic action (MSKCC) may add fluid and salt loss and shift lithium levels; consequence dehydration or lithium toxicity. Mitigation: electrolyte and lithium level checks.
  • Glucose-lowering drugs (insulin, glipizide, metformin): Monitor (theoretical) — additive hypoglycemia, inferred from one human case (Goksu 2010); consequence low blood sugar. Mitigation: more frequent glucose checks in the first weeks.
  • Potassium-raising drugs (spironolactone; ACE inhibitors such as lisinopril, which block a blood-pressure hormone): Monitor (theoretical) — dandelion is potassium-rich (Examine); consequence hyperkalemia (high blood potassium). Mitigation: a potassium check after starting.
  • Chemotherapy (paclitaxel, mitoxantrone): Monitor (theoretical) — the extract added to chemotherapy-induced cell death in culture (Nguyen 2019); human effect unknown, so consequence could be benefit or toxicity. Mitigation: disclosure to the oncology team.
  • Over-the-counter caffeine and diuretics (caffeine tablets, pamabrom): Monitor (theoretical) — caffeine is cleared by CYP1A2, suppressed in rats (Maliakal 2001), and diuretics add urine loss; consequence jitteriness or dehydration. Mitigation: lower intake if symptoms appear.
  • Diuretic supplements (dandelion leaf, horsetail, juniper, parsley): Monitor (theoretical) — additive diuretic effect (MSKCC); consequence fluid and potassium shifts. Mitigation: not stacking several.
  • Glucose-lowering supplements (berberine, cinnamon, chromium): Monitor (theoretical) — additive glucose lowering, given the hypoglycemia case (Goksu 2010); consequence low blood sugar. Mitigation: glucose checks when combining.
  • Daisy-family herbs (chamomile, echinacea, arnica, milk thistle): Caution in sensitized people (theoretical) — shared sesquiterpene-lactone allergens (Jovanović 2004); consequence dermatitis or allergic reactions. Mitigation: introducing one at a time.
  • Other interventions (radiotherapy, surgery): Monitor (theoretical) — no interaction data exist, so the consequence is unknown; disclosure to the treating team is the only sourced safeguard (MSKCC).

Populations who should avoid Dandelion Root:

  • People with hypersensitivity to dandelion or other plants of the Asteraceae (Compositae, daisy) family (EMA)
  • People with bile-duct obstruction, cholangitis (bile-duct inflammation), gallstones, liver disease or other biliary disease (EMA)
  • People told by a physician to restrict fluid intake (EMA)
  • Pregnant or breastfeeding women (EMA)
  • Children under 12 years (EMA)
  • Transplant recipients on cyclosporine, tacrolimus or sirolimus without drug-level monitoring (Kwan 2014; MSKCC)
  • People with curable cancers using it in place of recommended treatment (Johnson 2018a)

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Keeping proven treatment in place: Using dandelion only alongside oncologist-recommended therapy, never instead of it, mitigates the higher mortality seen when alternative medicine replaces treatment (Johnson 2018a).
  • Disclosure to the oncology team and pharmacist: Naming the product and dose before starting prevents unrecognized interactions with chemotherapy, tyrosine kinase inhibitors and immunosuppressants (MSKCC).
  • Drug-level checks after starting: For cyclosporine, tacrolimus or sirolimus, trough levels measured 1–2 weeks after starting mitigate toxic levels like those in the transplant case (Kwan 2014).
  • Liver screening: A baseline liver panel, no use with gallstones or bile-duct obstruction (EMA), and stopping at jaundice or rising liver tests mitigate herbal liver injury, flagged in a gastroenterology society guideline without member revenue at stake (Chalasani 2021).
  • Tolerance test in allergy-prone users: In people with eczema or daisy-family allergy, a single small first cup, with stopping at rash, itching or wheeze, limits allergic reactions (Jovanović 2004).
  • Glucose monitoring on diabetes drugs: Daily glucose checks for the first 2 weeks detect additive hypoglycemia early (Goksu 2010).
  • Traditional amounts: Intake within 1–5 g dried root per cup, 2–3 times daily (EMA), far below the 10–15 daily cups linked to oxalate injury (Moriarty 2013).
  • Potassium and kidney-function checks: On spironolactone, ACE inhibitors or with kidney disease, potassium and creatinine tested 2–4 weeks after starting mitigate hyperkalemia and kidney strain.
  • Separation from quinolone antibiotics: Dandelion taken at least 2 hours apart from ciprofloxacin or levofloxacin mitigates the lower peak levels seen in rats (Zhu 1999).
  • Contaminant-tested products: Third-party tested roots reduce lead exposure reported in some teas (ConsumerLab).

Therapeutic Protocol

Timing, splitting, titration and other parameters without a citation reflect common practice.

  • No established cancer protocol: No oncology guideline or completed trial defines a dandelion root dose for cancer; the regimens below come from a regulator’s traditional-use monograph, case reports and the Windsor group.
  • Regulatory traditional-use dose: 1–5 g dried root as a decoction (root simmered in water) in 150 mL water, 2–3 times daily, for digestive, appetite and urinary uses, not cancer (EMA).
  • Windsor tea regimen: Three cups of dandelion root tea daily, used by leukemia patients reported by oncologist Caroline Hamm, whose group popularized the approach (Hamm 2013).
  • Capsule regimen from a case report: Two 520 mg capsules once daily, alongside papaya leaf tea and many supplements (Rahmat & Damon 2018).
  • Trial formulation: A freeze-dried concentrated extract made by AOR for the Windsor trial was described as 6–10 times more potent than retail tea; its dose was not published (CBC).
  • Competing approaches: Conventional oncology uses no dandelion; integrative oncology treats it as a supplement to disclose and screen (MSKCC); some patients use it as sole therapy (Hamm 2013).
  • Best time of day: No cancer data; for appetite, preparations are taken ½ hour before meals (EMA). Morning-to-afternoon dosing avoids nighttime urination.
  • Half-life: Not established in humans; only a rat study of taraxasterol exists (Zhang 2015).
  • Single versus split doses: Sources split intake 2–3 times daily (EMA); Windsor patients took three cups daily (Hamm 2013), with no report of how intake was spread.
  • Genetic polymorphisms: No pharmacogenetic data guide dosing; CYP3A4 or CYP1A2 status matters only through interacting drugs.
  • Sex-based differences: No sex differences in response or dosing have been studied; hormone-sensitive cancers warrant extra caution (Oh 2015).
  • Age-related considerations: Reported patients were 60–76 years old; no age-specific dosing data exist, and lower kidney function in older adults matters given the oxalate case (Moriarty 2013).
  • Baseline biomarker levels: No biomarker predicts response; liver tests, potassium and creatinine decide whether starting is reasonable.
  • Pre-existing health conditions: Biliary disease excludes use (EMA); kidney disease and transplantation are the settings of the reported oxalate and drug-level cases (Moriarty 2013; Kwan 2014).

Discontinuation & Cycling

  • Lifelong or short-term: No evidence defines duration for cancer; the EU traditional-use monograph advises medical review if symptoms persist beyond 2 weeks (EMA), while case-report patients continued for months to years.
  • Withdrawal effects: No physiological withdrawal syndrome is reported. In case reports, monocyte counts rose when intake fell below three cups daily, and one remission relapsed after 3 months (Hamm 2013).
  • Tapering: No tapering protocol exists or appears necessary; stopping is abrupt in practice, with blood counts rechecked 2–4 weeks later in blood cancers.
  • Cycling: No data support cycling to maintain efficacy; reported users took it continuously (Rahmat & Damon 2018).
  • Stopping triggers: Rash, jaundice, low blood sugar, rising liver tests or high potassium are reasons to stop and seek review.

Sourcing and Quality

  • Plant part: The cancer studies used root, not leaf or flower; in one study leaf, flower and root extracts acted differently on cancer cells (Sigstedt 2008).
  • Extract type: The Windsor work used a hot-water root extract (Ovadje 2016); ethanol and methanol extracts were used elsewhere, and an ethanol extract showed estrogenic activity that has not been tested for hot-water root extract (Oh 2015).
  • Roasted versus unroasted: Roasted “dandelion coffee” products are untested in cancer studies, which used unroasted dried root.
  • Species: Taraxacum officinale is the studied species for root work; Chinese products may contain Taraxacum mongolicum or other species with different chemistry (Cui 2026).
  • Contaminants: Lead has been reported in some teas (ConsumerLab); Examine advises against eating wild urban dandelions because of pesticide exposure (Examine).
  • What to look for: Third-party certification (USP Verified from the United States Pharmacopeia, NSF Certified, or ConsumerLab-approved), a stated plant part and species, and lot-specific heavy-metal testing.
  • Brands: No retail brand has been tested in cancer studies; the Windsor trial extract was a research product made by AOR, a Calgary natural-health-product company (CBC).

Practical Considerations

  • Time to effect: Unknown in controlled studies; the reported leukemia remissions appeared within weeks to months of starting tea (Hamm 2013).
  • Common pitfalls: Treating cell-dish results as clinical proof, believing the viral “98% in 48 hours” claim (PolitiFact), stopping proven therapy, confusing leaf with root, and overlooking drug interactions.
  • Regulatory status, United States: Sold as a dietary supplement, which may not legally claim to treat, cure or prevent disease (FDA).
  • Regulatory status, European Union: A traditional herbal medicinal product for digestive, appetite and urinary uses; cancer is not an indication (EMA).
  • Regulatory status, Canada: The Windsor investigators state Health Canada authorized a Phase I (first-in-human safety and dose-finding) trial (Ovadje 2016); no record appears in Health Canada’s drug-trial portal (Health Canada).
  • Cost and access: Dandelion root is inexpensive and widely available; cost is not a barrier.
  • Funding incentives: Insurers would gain from an inexpensive effective cancer therapy, so payer incentives do not explain the evidence gap; the unpatentable raw herb draws little industry funding, while the Windsor lead scientist is a named patent inventor (US10179156B2) with a company role (PolitiFact).

Interaction with Foundational Habits

  • Sleep: Indirect. No sleep studies exist; the root’s traditional use to increase urine flow (EMA) can cause nighttime urination if taken late, so dosing before mid-afternoon protects sleep.
  • Nutrition: Potentiating. The root is rich in inulin (a prebiotic fiber that feeds gut bacteria), adding to dietary fiber and possibly causing gas; adequate fluid intake is advised with the urinary indication (EMA), and dandelion is potassium-rich (Examine).
  • Exercise: None known. No studies link dandelion root to training response; its diuretic effect adds to the fluid and electrolyte loss of heavy sweating.
  • Stress management: None known. No data show effects on cortisol (the main stress hormone) or the stress response.

Monitoring Protocol & Defining Success

Before starting, a baseline panel is drawn so that later changes can be attributed: blood counts, liver tests, potassium, creatinine and fasting glucose, plus the cancer’s own markers or imaging and any drug levels. Baseline testing matters most for people on interacting drugs, with kidney or bile-duct disease, or with blood cancers, where blood counts are the main readout (Hamm 2013).

Ongoing monitoring follows this cadence: at 2 weeks (drug levels, glucose, potassium), at 6 weeks, then every 3 months alongside routine oncology visits. Success means stable or improving disease on the standard markers and imaging the oncology team already uses, with no new liver, kidney or drug-level problems. Because dandelion is taken alongside treatment, any improvement cannot by itself be credited to dandelion.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Complete blood count with differential White cells 4.0–11.0 × 10⁹/L; monocytes 0.2–1.0 × 10⁹/L (standard reference range) Expected to change: blood-cancer readout Main outcome in leukemia case reports (Hamm 2013); ranges vary by laboratory; no fasting needed
Tumor-specific markers and imaging No established target; track change from the individual’s own baseline Expected to change: disease burden The markers the oncology team already follows (e.g., PSA, prostate-specific antigen; CEA, carcinoembryonic antigen); results are comparable only with the same lab and method each time
ALT, AST, alkaline phosphatase, bilirubin ALT 7–56 U/L; AST 10–40 U/L; alkaline phosphatase 44–147 U/L; bilirubin 0.1–1.2 mg/dL (standard reference range) Safety check: stop if rising ALT and AST are liver-cell enzymes; alkaline phosphatase and bilirubin track bile flow; biliary disease excludes use (EMA); herbal liver injury per a gastroenterology society guideline, no member revenue at stake (Chalasani 2021)
Serum potassium 3.5–5.0 mmol/L (standard reference range) Safety check: changes use Dandelion is potassium-rich (Examine); most relevant with spironolactone, ACE inhibitors or kidney disease; hemolyzed (damaged red cell) samples falsely raise potassium
Serum creatinine 0.6–1.3 mg/dL (standard reference range) Safety check: changes use Kidney function; oxalate injury occurred in kidney disease (Moriarty 2013); pair with potassium
Fasting glucose 70–99 mg/dL (standard reference range) Safety check: changes use Hypoglycemia case (Goksu 2010); 8–12 hour fast; most relevant on insulin or sulfonylureas (oral glucose-lowering drugs such as glipizide)
Trough levels of narrow-margin drugs (tacrolimus, cyclosporine, sirolimus) No established target for this use; track against the prescriber’s individual target before and after starting Safety check: changes dosing Drawn just before the next dose; toxic levels in a multi-herb tea case (Kwan 2014)

Qualitative markers:

  • Appetite and digestion (fullness, gas, bloating)
  • Urination frequency, especially at night
  • Skin rash, itching or wheeze after use
  • Symptoms of low blood sugar (shakiness, sweating, confusion)
  • Yellowing of skin or eyes, dark urine or itching (bile-flow problems)
  • Energy, fatigue and overall well-being during cancer treatment

Emerging Research

  • Windsor Phase I trial (no NCT ID, the ClinicalTrials.gov registry number): Dose-finding study of concentrated extract in about 30 patients with treatment-resistant blood cancers (CBC); not ongoing, it stalled for low recruitment and funding, with no results (PolitiFact). Positive results would justify larger trials; null results would leave only case reports.
  • No registered trials: A ClinicalTrials.gov search for dandelion or Taraxacum on 2026-10-23 found 23 records, none in cancer, so no registered study can soon supply human efficacy data; a newly registered controlled trial would be the first test able to change this review’s grades.
  • Isolated constituents: Taraxasterol shows anticancer activity in models (Jiao 2022), which could yield a defined drug candidate; however, isolated triterpenes were weaker than whole extract (Ovadje 2016), which weakens the single-compound path.
  • Drug-interaction studies: Calls for human pharmacokinetic work with tyrosine kinase inhibitors (Renna 2025) follow a rat signal (Alzoman 2019); confirmed interactions would weaken the case for combining dandelion with targeted leukemia drugs.
  • Hormonal safety: Estrogen-like activity of a dandelion extract (Oh 2015) needs testing with root preparations; confirmation would argue against use in hormone-sensitive cancers.
  • Supportive care: A water root extract reduced cisplatin kidney injury in animals (Hu 2025); human confirmation would shift interest from tumor killing to protecting patients during chemotherapy.
  • Evidence synthesis: The 2026 systematic review found only preclinical anticancer data and a favorable safety record (Cui 2026); a first controlled human study would change its conclusion.

Conclusion

Dandelion root is an inexpensive, widely sold herb whose water extract kills many kinds of cancer cells in laboratory dishes and slows tumor growth in mice while sparing healthy cells in those same experiments. Those findings are real but early, and some laboratory work points the other way. In people, the evidence consists of a handful of reports of leukemia patients whose blood counts improved while drinking dandelion tea, often after chemotherapy and alongside other remedies, so the cause of those improvements cannot be separated out. The one planned human trial never reported results.

The main dangers are not from the root itself, which appears mild in food amounts, but from what surrounds its use. People who use unproven remedies in place of standard cancer care die sooner, dandelion can change blood levels of some important medicines, and people with daisy-family allergies, bile-duct disease or kidney problems face added risk. A possible estrogen-like effect leaves hormone-driven cancers an open question.

The research base is thin and comes largely from one Canadian group whose lead scientists are named inventors on a patent for the extract and, in one case, hold a company role, which matters when weighing their optimism. For a health-focused adult with cancer, the evidence supports seeing dandelion root as an unproven add-on whose benefit in people is unknown, whose risks are mostly manageable, and whose biggest hazard is displacing treatments that work.

Top - Benefits - Risks - Protocol